Meeting
2014 ASCO Annual Meeting
Phase II study of vemurafenib in patients with locally advanced, unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
Authors
Sigrun Hallmeyer
Oncology Specialists, SC, Niles, IL
Sigrun Hallmeyer , Omid Hamid , Thuy Anh Sorof , Yong Mun , Shiyao Liu , Sarang Abhyankar , Geoffrey Thomas Gibney , Igor Puzanov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01586195
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9075^)
DOI
10.1200/jco.2014.32.15_suppl.9075
Abstract #
9075^
Poster Bd #
279
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.
First Author: Lotte Marieke Knapen
Poster
2014 ASCO Annual Meeting
A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal
Poster
2017 ASCO Annual Meeting
A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
First Author: Jose A. Lopez-Martin
Poster
2015 ASCO Annual Meeting
One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal